Average price target for Vertex Pharmaceuticals stock raised to $580.63
Analysts lifted the average 12-month price target for VRTX to $580.63, implying about 5% upside, according to TradingView citing FactSet data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Estimates from 27 analysts show the average price target for Vertex Pharmaceuticals shares rising from $575.96 to $580.63. Individual forecasts range from $350 to $667 per share. According to TradingView, which relies on FactSet data, the updated target implies roughly 5% potential upside based on the November 2 closing price.
The consensus rating stays at Buy. Of the 35 analysts covering the stock, 27 rate it Buy, 6 Hold and 2 Sell.
why it matters
This is a routine development: a target revision reflects analysts updating their models rather than new information about the company itself. Such changes mainly serve as a gauge of sentiment toward the stock, so the impact on the broader market is expected to be limited.
tags
instruments
sources
- Vertex Pharmaceuticals Incorporated Stock 12‑Month Price Target Raised to $580.63, Implies 5% Upside — TradingView, 3 November 2026 at 07:20 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗